Despite increasing spend on R&D, 96 percent of potential drugs never make it to market.
Challenges such as access to accurate data, excessive costs, steep regulatory burdens, and the quick pace of the market make it difficult for researchers to discover novel therapies and successfully commercialize them.
This is changing, however. Advances in artificial intelligence (AI) and machine learning make it faster and more efficient for life sciences professionals to identify antibodies, validate targets, analyze chemical structures and run patent searches. It is also enabling scientists to comb through millions of global data points, segment them by relevance and connect them together in a way that makes sense.
Download this white paper by PatSnap to find out:
- How connected innovation intelligence (CII) is enabling organizations to accelerate pharmaceutical innovation
- How to leverage AI-powered technology to simplify complex search results and identify early-stage innovation opportunities
- Ways CII can be utilized to connect patent, litigation, and non-patent literature in an accessible manner